Finch Therapeutics Group (NASDAQ:FNCH) Trading Up 0.8% – Should You Buy?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH)’s stock price rose 0.8% during mid-day trading on Tuesday . The company traded as high as $12.13 and last traded at $12.05. Approximately 5,118 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 28,449 shares. The stock had previously closed at $11.95.

Finch Therapeutics Group Trading Up 0.8 %

The company has a 50-day moving average price of $11.93 and a 200 day moving average price of $6.09. The stock has a market capitalization of $19.40 million, a P/E ratio of -1.37 and a beta of 1.34.

Finch Therapeutics Group (NASDAQ:FNCH) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($3.01) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Finch Therapeutics Group

A hedge fund recently bought a new stake in Finch Therapeutics Group stock. Lake Street Advisors Group LLC purchased a new position in shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 21,206 shares of the company’s stock, valued at approximately $56,000. Lake Street Advisors Group LLC owned 1.32% of Finch Therapeutics Group as of its most recent filing with the Securities and Exchange Commission. 21.77% of the stock is currently owned by institutional investors and hedge funds.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.